Arrowhead Pharmaceuticals, Inc. ARWR NASDAQ

Arrowhead Pharmaceuticals, Inc. (ARWR) generated $179.55M in operating cash flow for fiscal year 2025. After capital expenditures of $22.67M, free cash flow was $156.89M.

Free cash flow margin was 18.9% of revenue. Cash conversion ratio was 5.96x, indicating earnings are backed by cash.

Criteria supported by this page:

• HEALTH (50/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
• MOAT (66/100, Partial) — cash flow generation is present but not at levels indicating a wide moat
• INCOME (10/100) — Cash conversion ratio was 5.96x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 46/100 with 2/7 criteria passed.